JPWO2022146484A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022146484A5 JPWO2022146484A5 JP2023540514A JP2023540514A JPWO2022146484A5 JP WO2022146484 A5 JPWO2022146484 A5 JP WO2022146484A5 JP 2023540514 A JP2023540514 A JP 2023540514A JP 2023540514 A JP2023540514 A JP 2023540514A JP WO2022146484 A5 JPWO2022146484 A5 JP WO2022146484A5
- Authority
- JP
- Japan
- Prior art keywords
- coronavirus
- polypeptide
- seq
- mutation
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims 54
- 108090000765 processed proteins & peptides Proteins 0.000 claims 54
- 230000035772 mutation Effects 0.000 claims 46
- 241000711573 Coronaviridae Species 0.000 claims 34
- 102000002067 Protein Subunits Human genes 0.000 claims 18
- 108700023317 Coronavirus Receptors Proteins 0.000 claims 17
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 16
- 102000005962 receptors Human genes 0.000 claims 13
- 108020003175 receptors Proteins 0.000 claims 13
- 238000002864 sequence alignment Methods 0.000 claims 11
- 229960005486 vaccine Drugs 0.000 claims 8
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 6
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims 5
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims 5
- 101710204410 Scaffold protein Proteins 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 4
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 4
- 208000025370 Middle East respiratory syndrome Diseases 0.000 claims 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 229940096437 Protein S Drugs 0.000 claims 3
- 101710198474 Spike protein Proteins 0.000 claims 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000002086 nanomaterial Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims 1
- 235000020778 linoleic acid Nutrition 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063132863P | 2020-12-31 | 2020-12-31 | |
| US63/132,863 | 2020-12-31 | ||
| US202163188651P | 2021-05-14 | 2021-05-14 | |
| US63/188,651 | 2021-05-14 | ||
| PCT/US2021/037341 WO2022146484A1 (fr) | 2020-12-31 | 2021-06-15 | Protéines de coronavirus stables et compositions de vaccin associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024502823A JP2024502823A (ja) | 2024-01-23 |
| JPWO2022146484A5 true JPWO2022146484A5 (fr) | 2024-06-24 |
Family
ID=82260758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540514A Pending JP2024502823A (ja) | 2020-12-31 | 2021-06-15 | 安定なコロナウィルスタンパク質およびそのワクチン組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4271698A1 (fr) |
| JP (1) | JP2024502823A (fr) |
| KR (1) | KR20230135598A (fr) |
| AU (1) | AU2021415906A1 (fr) |
| BR (1) | BR112023013138A2 (fr) |
| CA (1) | CA3201697A1 (fr) |
| CL (1) | CL2023001930A1 (fr) |
| CO (1) | CO2023008898A2 (fr) |
| PE (1) | PE20241316A1 (fr) |
| WO (1) | WO2022146484A1 (fr) |
| ZA (1) | ZA202305698B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024130083A1 (fr) * | 2022-12-15 | 2024-06-20 | Mayo Foundation For Medical Education And Research | Virus de rougeole modifiés pour le traitement d'infections à coronavirus |
| TW202500574A (zh) * | 2023-05-12 | 2025-01-01 | 美商伊科薩瓦克斯有限公司 | 冠狀病毒刺突醣蛋白受體結合域及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113150084B (zh) * | 2021-03-23 | 2023-03-21 | 江苏坤力生物制药有限责任公司 | 一种纳米化的冠状病毒抗原及其应用 |
-
2021
- 2021-06-15 WO PCT/US2021/037341 patent/WO2022146484A1/fr active Application Filing
- 2021-06-15 PE PE2023001906A patent/PE20241316A1/es unknown
- 2021-06-15 EP EP21916103.1A patent/EP4271698A1/fr active Pending
- 2021-06-15 KR KR1020237026138A patent/KR20230135598A/ko active Pending
- 2021-06-15 CA CA3201697A patent/CA3201697A1/fr active Pending
- 2021-06-15 BR BR112023013138A patent/BR112023013138A2/pt unknown
- 2021-06-15 JP JP2023540514A patent/JP2024502823A/ja active Pending
- 2021-06-15 AU AU2021415906A patent/AU2021415906A1/en active Pending
-
2023
- 2023-05-26 ZA ZA2023/05698A patent/ZA202305698B/en unknown
- 2023-06-29 CL CL2023001930A patent/CL2023001930A1/es unknown
- 2023-07-05 CO CONC2023/0008898A patent/CO2023008898A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhu et al. | Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity | |
| Malczyk et al. | A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform | |
| Amanat et al. | Introduction of two prolines and removal of the polybasic cleavage site lead to higher efficacy of a recombinant spike-based SARS-CoV-2 vaccine in the mouse model | |
| Arndt et al. | A conserved domain in the coronavirus membrane protein tail is important for virus assembly | |
| Kim et al. | Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles | |
| Escors et al. | The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability | |
| RU2011128371A (ru) | Модифицированные f протеины sv и способы их применения | |
| Zhang et al. | The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM. WU | |
| Klupp et al. | The capsid-associated UL25 protein of the alphaherpesvirus pseudorabies virus is nonessential for cleavage and encapsidation of genomic DNA but is required for nuclear egress of capsids | |
| Agnihothram et al. | Development of a broadly accessible Venezuelan equine encephalitis virus replicon particle vaccine platform | |
| JP4875274B2 (ja) | キメラアルテリウィルス様粒子 | |
| WO2021244120A1 (fr) | Vaccin contre le sars-cov-2 | |
| CN107022008A (zh) | 广谱地抑制人类冠状病毒感染的多肽及其应用 | |
| DK201170227A (en) | Piscine reovirus immunogenic compositions | |
| CN110430895B (zh) | 脊髓灰质炎疫苗 | |
| JP2004502460A5 (fr) | ||
| US20070185027A1 (en) | Antiviral agents for the treatment, control and prevention of infections by coronaviruses | |
| WO2006136448A2 (fr) | Sras attenue: utilisation comme vaccin | |
| Ahmadpour et al. | Impact of circulating SARS-CoV-2 mutant G614 on the COVID-19 pandemic | |
| Warrier et al. | Role of sindbis virus capsid protein region II in nucleocapsid core assembly and encapsidation of genomic RNA | |
| JPWO2022146484A5 (fr) | ||
| Dietzel et al. | Canine distemper virus matrix protein influences particle infectivity, particle composition, and envelope distribution in polarized epithelial cells and modulates virulence | |
| CN119013040A (zh) | 冠状病毒疫苗 | |
| WO2021207848A1 (fr) | Vaccin contre le mers-cov | |
| Diaz-Mitoma | Enveloped virus-like particles as a platform for vaccine development |